Navigation Links
Biocept, Inc. Announces CEO and Director Appointments
Date:10/6/2008

SAN DIEGO, Oct. 6 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Stephen M. Coutts, Ph.D. as CEO, President and Director and the appointment of Edward A. Dennis, Ph.D., as Director. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. Janko.

"We are pleased to welcome Dr. Coutts, a highly regarded professional in our field, and believe he is a good fit with our development strategy," said Claire K.T. Reiss, Chairman of the Board. "In addition, we are honored to add Dr. Dennis to the Board and look forward to benefiting from his extensive experience and perspective. On behalf of the Biocept Board of Directors, I would also like to thank Mr. Janko for his contributions during the five years that he led Biocept," Ms. Reiss added.

"I am delighted to join Biocept at this critical time and look forward to continuing to develop and grow this exciting technology," said Dr. Coutts.

Dr. Coutts has 30 years of experience in the pharmaceutical and biotechnical industries. He was most recently Director of Pharmaceutical Development at Cypress Bioscience, Inc. and a principal at Alembic Biotech Consultants. He was previously President and COO at Triad Therapeutics, Inc. and spent 11 years as Executive Vice President for R&D at La Jolla Pharmaceutical. Dr. Coutts holds a BS in Chemistry from San Diego State University, a Ph.D. in Biochemistry from Harvard University and an MBA from New York University.

Dr. Dennis is Distinguished Professor of Chemistry and Biochemistry and of Pharmacology in the School of Medicine at the University of California at San Diego (UCSD). He is currently Editor-in-Chief of the Journal of Lipid Research and has been named a Fellow of the American Association for the Advancement of Sciences. Dr. Dennis serves on the Scientific Advisory Board and Board of Directors of several private and public companies. He received his BA from Yale University and a Ph.D. from Harvard University.

About Biocept

Biocept, an emerging biotechnology leader, engineers novel microfluidic devices that provide the foundation for a new class of diagnostic assays. Biocept is based in San Diego, California, a major center for academic and industrial life sciences research. Founded in 1997, the company is privately held and draws on a team rich in experience in life science. Its CLIA clinical laboratory is accredited by the College of American Pathologists and holds licenses in California and other states as required.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Glemser Announces New Labeling Solution: SPL for DCM Addresses New SPL Release 4 Requirements
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners
4. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
5. SyntheMed Announces New Management Appointments
6. Alba Therapeutics Corporation Announces Promotions
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. 23andMe Announces Breast Cancer Initiative
9. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
11. Synthetech Announces New Director of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selector™ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
(Date:12/7/2016)... ... 2016 , ... A new study published in the just-published ... advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue ... sampling may improve the value of a blood-based test.” The study was conducted ...
(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dr. Dan Kephart as its chief science ... will assume his responsibilities at Neogen effective Jan. 1. ... director for the agribusiness unit of Thermo Fisher Scientific, ... at Life Technologies. His extensive industry experience also includes ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):